{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:55:46Z","timestamp":1786589746207,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81500474"],"award-info":[{"award-number":["81500474"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.thromres.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T06:39:05Z","timestamp":1525761545000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"167","author":[{"given":"Miaomiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingxue","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6739","authenticated-orcid":false,"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1055\/s-0035-1550439","article-title":"Splanchnic vein thrombosis","volume":"41","author":"Valla","year":"2015","journal-title":"Semin. Thromb. Hemost."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11739-010-0413-6","article-title":"Splanchnic vein thrombosis: clinical presentation, risk factors and treatment","volume":"5","author":"De Stefano","year":"2010","journal-title":"Intern. Emerg. Med."},{"issue":"2","key":"10.1016\/j.thromres.2018.05.007_bb0015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/th15-04-0326","article-title":"Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment","volume":"115","author":"De Stefano","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"25","key":"10.1016\/j.thromres.2018.05.007_bb0020","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1182\/blood-2011-09-376517","article-title":"Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis","volume":"120","author":"Smalberg","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0025","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1055\/s-2007-996117","article-title":"Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis","volume":"23","author":"De Stefano","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0168-8278(02)00434-8","article-title":"Budd-Chiari syndrome: a review by an expert panel","volume":"38","author":"Janssen","year":"2003","journal-title":"J. Hepatol."},{"issue":"9464","key":"10.1016\/j.thromres.2018.05.007_bb0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"9501","key":"10.1016\/j.thromres.2018.05.007_bb0040","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.thromres.2018.05.007_bb0045","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0050","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0055","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.thromres.2018.05.007_bb0060","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1182\/blood-2007-11-125328","article-title":"The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases","volume":"111","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2018.05.007_bb0065","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/j.1365-2036.2011.04627.x","article-title":"Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis","volume":"33","author":"Qi","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0070","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0962-8924(01)01926-2","article-title":"The ins and outs of calreticulin: from the ER lumen to the extracellular space","volume":"11","author":"Johnson","year":"2001","journal-title":"Trends Cell Biol."},{"issue":"21","key":"10.1016\/j.thromres.2018.05.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3198.3198","article-title":"On the absence of calreticulin (CALR) mutations in chronic myeloprolierative neoplasms (MPNs) with splanchnic venous thrombosis (SVT): experience from a single institution","volume":"124","author":"Martino","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0085","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjh.13121","article-title":"Incidence of CALR mutations in patients with splanchnic vein thrombosis","volume":"168","author":"Haslam","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2018.05.007_bb0090","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jhep.2014.08.032","article-title":"Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis","volume":"62","author":"Turon","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.thromres.2018.05.007_bb0095","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/bjh.13314","article-title":"CALR mutations screening should not be studied in splanchnic vein thrombosis","volume":"170","author":"Castro","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0100","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.3324\/haematol.2014.120857","article-title":"Somatic calreticulin mutations in patients with Budd-Chiari syndrome and portal vein thrombosis","volume":"100","author":"Plompen","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2018.05.007_bb0105","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S0168-8278(15)30092-1","article-title":"CALR somatic mutations in a prospective cohort of 308 patients with splanchnic vein thrombosis","volume":"62","author":"Marzac","year":"2015","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0110","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1160\/TH14-12-1055","article-title":"Clinical utility of screening for CALR gene exon 9 mutations in patients with splanchnic venous thrombosis","volume":"113","author":"Colaizzo","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0115","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/MEG.0000000000000526","article-title":"CALR mutations in Chinese Budd-Chiari syndrome patients","volume":"28","author":"Zhang","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.thromres.2018.05.007_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bjh.13235","article-title":"Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis","volume":"169","author":"Roques","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.thromres.2018.05.007_bb0130","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp. Clin. Trials"},{"issue":"7414","key":"10.1016\/j.thromres.2018.05.007_bb0135","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.thromres.2018.05.007_bb0140","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.thromres.2018.05.007_bb0145","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/bjh.13756","article-title":"Calreticulin mutations and their importance in splanchnic vein thrombosis","volume":"174","author":"Sekhar","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2018.05.007_bb0150","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.12.010","article-title":"CALR exon 9 mutations in idiopathic splanchnic vein thrombosis in an Australian cohort","volume":"150","author":"Ho","year":"2017","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0155","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2017.06.017","article-title":"Calreticulin mutations and their importance in Budd-Chiari syndrome","volume":"67","author":"Jain","year":"2017","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0160","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.22772","article-title":"Vascular disorders of the liver","volume":"49","author":"DeLeve","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.thromres.2018.05.007_bb0165","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"de Franchis","year":"2015","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.thromres.2018.05.007_bb0170","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.944.944","article-title":"The effect of initial molecular profile on response to recombinant interferon alpha (rIFN\u03b1) treatment in early myelofibrosis","volume":"128","author":"Silver","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2018.05.007_bb0175","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.14958","article-title":"Distinct clinical, laboratory and molecular features of myeloproliferative neoplasm patients with splanchnic vein thrombosis","author":"How","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"20","key":"10.1016\/j.thromres.2018.05.007_bb0180","doi-asserted-by":"crossref","first-page":"e3355","DOI":"10.1097\/MD.0000000000003355","article-title":"gamma-Glutamyl transferase is an independent biomarker of splanchnic thrombosis in patients with myeloproliferative neoplasm","volume":"95","author":"Gortzen","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0185","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1440-1746.2011.07040.x","article-title":"Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study","volume":"27","author":"Qi","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"25","key":"10.1016\/j.thromres.2018.05.007_bb0190","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11\u221212","key":"10.1016\/j.thromres.2018.05.007_bb0195","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.13815","article-title":"Review article: the aetiology of primary Budd-Chiari syndrome - differences between the West and China","volume":"44","author":"Qi","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.thromres.2018.05.007_bb0200","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1160\/TH12-10-0784","article-title":"Thrombotic risk factors in Chinese Budd-Chiari syndrome patients. An observational study with a systematic review of the literature","volume":"109","author":"Qi","year":"2013","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0205","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/jgh.12140","article-title":"Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study","volume":"28","author":"Cheng","year":"2013","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.thromres.2018.05.007_bb0210","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.thromres.2018.05.007_bb0215","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2018.05.007_bb0220","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.thromres.2018.05.007_bb0225","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2018.05.007_bb0230","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818303396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818303396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T18:07:18Z","timestamp":1604254038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818303396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":46,"alternative-id":["S0049384818303396"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.05.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}